Massive Bio Co-Founders To Attend ASH Annual Meeting and Exposition
Massive Bio Co-Founders Selin Kurnaz, PhD, and Arturo Loaiza-Bonilla, MD, will be among the attendees at the 64th ASH Annual Meeting and Exposition, one of the most important events in the field of hematology, which will take place on December 10-13, 2022, in New Orleans, Louisiana.
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition will be held at the Ernest N. Morial Convention Center in New Orleans, Louisiana, from December 10-13, 2022. Among the attendees at this annual event will be two co-founders of Massive Bio, a global industry leader in connecting patients to clinical trials using artificial intelligence and concierge-level services: Chief Executive Officer Selin Kurnaz, PhD, and Chief Medical Officer Arturo Loaiza-Bonilla, MD, MSEd. The ASH Annual Meeting is one of the most important events in the world of hematology, and will highlight the latest developments, new treatments, and current research in blood diseases, including malignant hematology, an intense area of focus for Massive Bio.
As every year, the 64th ASH Annual Meeting will include a variety of scientific and educational programs. General sessions will include the prestigious Plenary Scientific Session, Best of ASH, and Presidential Symposium. Special-interest sessions will feature an update on progress in sickle-cell disease and the introduction of ASH’s Choosing Wisely Champions initiative, among many other sessions. This year’s meeting will also include special sessions on Diversity, Equality, and Inclusion, with the goal of improving outcomes for all patients with blood diseases. Training activities will include ASH-a-Palooza and the Trainee Didactic Sessions, which provide content of interest to undergraduates, medical and graduate students, residents, and fellows.
This in-person event will also be broadcast virtually, and access to the meeting’s virtual platform will be provided with registration.
Recent In Massive Bio
Massive Bio Continues Webinar Series
The New Issue of Massive Bio Magazine is Now Available
Massive Bio Announces Plans to Expand AI Use in Oncology, from Clinical Trial Matching to Drug Matching and Beyond
Massive Bio CEO Selin Kurnaz is Featured in the Wall Street Journal
Massive Bio Supports Cancer Associations